Summary
Camba-Pharma has a registered holding activity and consists mainly of financial fixed assets; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €137,100 and a net result of €47,651. Equity is growing by about 40% per year across the filed financial years. Its solvency ranks better than 48% of 22,576 sector peers (NACE 47, financial year 2025). The company has been active since 2019 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
29-12
Gazette deed
Resignation: Camille BAETSLÉ (director)Appointment: Camille BAETSLÉ (director) · Amendment of the articles · Capital conversion9 facts ▸
- General meeting, 21-12-2023
- Amendment of the articles (2 times)
- Capital conversion, “statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
- Capital
- Power of attorney, Jessica Verhaeghe
- Director resignation, Camille BAETSLÉ (director)
- Director appointment, Camille BAETSLÉ (director (not named in the articles))
- Director discharge, Camille BAETSLÉ
- Registered office clause, “Droogveldeweg 7, zevende besluit algemene vergadering” (deed in Dutch)
About the unread acts
Of the 4 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 3 have not been read yet: what they contain is neither established nor disproved here.